Clinical Trial

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

Study acronym: ADITI-1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-31; most recent amendment 2026-01-12.
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT06755450
Lead Sponsor Aurigene Discovery Technologies Limited
Conditions Relapsed Advanced Lymphomas
Enrollment 40 participants
Start Date 2025-01-15
Primary Completion 2027-01-15 (estimated)
Study Completion 2028-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-13